Search­ing for ways to boost CAR-T re­sponse, Penn re­searchers find a ca­pa­ble wing­man in BET in­hibitors

A whole in­dus­try may have been born out of the spec­tac­u­lar suc­cess of CD19 CAR-T, push­ing the en­ve­lope on next-gen­er­a­tion con­structs hit­ting new tar­gets. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER